<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sun C</submitter><funding>NHLBI NIH HHS</funding><pagination>396</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6529459</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(6)</volume><pubmed_abstract>Ca&lt;sup>2+&lt;/sup> oscillation is a system-level property of the cellular Ca&lt;sup>2+&lt;/sup>-handling machinery and encodes diverse physiological and pathological signals. The present study tests the hypothesis that Ca&lt;sup>2+&lt;/sup> oscillations play a vital role in maintaining the stemness of liver cancer stem cells (CSCs), which are postulated to be responsible for cancer initiation and progression. We found that niche factor-stimulated Ca&lt;sup>2+&lt;/sup> oscillation is a signature feature of CSC-enriched Hep-12 cells and purified α2δ1&lt;sup>+&lt;/sup> CSC fractions from hepatocellular carcinoma cell lines. In Hep-12 cells, the Ca&lt;sup>2+&lt;/sup> oscillation frequency positively correlated with the self-renewal potential. Using a newly developed high signal, endoplasmic reticulum (ER) localized Ca&lt;sup>2+&lt;/sup> sensor GCaMP-ER2, we demonstrated CSC-distinctive oscillatory ER Ca&lt;sup>2+&lt;/sup> release controlled by the type 2 inositol 1,4,5-trisphosphate receptor (IP&lt;sub>3&lt;/sub>R2). Knockdown of IP&lt;sub>3&lt;/sub>R2 severely suppressed the self-renewal capacity of liver CSCs. We propose that targeting the IP&lt;sub>3&lt;/sub>R2-mediated Ca&lt;sup>2+&lt;/sup> oscillation in CSCs might afford a novel, physiologically inspired anti-tumor strategy for liver cancer.</pubmed_abstract><journal>Cell death &amp; disease</journal><pubmed_title>Central role of IP&lt;sub>3&lt;/sub>R2-mediated Ca&lt;sup>2+&lt;/sup> oscillation in self-renewal of liver cancer stem cells elucidated by high-signal ER sensor.</pubmed_title><pmcid>PMC6529459</pmcid><funding_grant_id>R24 HL120847</funding_grant_id><pubmed_authors>Liu H</pubmed_authors><pubmed_authors>Lee JC</pubmed_authors><pubmed_authors>Doran R</pubmed_authors><pubmed_authors>Sun C</pubmed_authors><pubmed_authors>Zhao W</pubmed_authors><pubmed_authors>Sun T</pubmed_authors><pubmed_authors>Kotlikoff MI</pubmed_authors><pubmed_authors>Li W</pubmed_authors><pubmed_authors>Lee FK</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Shui B</pubmed_authors><pubmed_authors>Shen QS</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Reining S</pubmed_authors><pubmed_authors>Cheng H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Central role of IP&lt;sub>3&lt;/sub>R2-mediated Ca&lt;sup>2+&lt;/sup> oscillation in self-renewal of liver cancer stem cells elucidated by high-signal ER sensor.</name><description>Ca&lt;sup>2+&lt;/sup> oscillation is a system-level property of the cellular Ca&lt;sup>2+&lt;/sup>-handling machinery and encodes diverse physiological and pathological signals. The present study tests the hypothesis that Ca&lt;sup>2+&lt;/sup> oscillations play a vital role in maintaining the stemness of liver cancer stem cells (CSCs), which are postulated to be responsible for cancer initiation and progression. We found that niche factor-stimulated Ca&lt;sup>2+&lt;/sup> oscillation is a signature feature of CSC-enriched Hep-12 cells and purified α2δ1&lt;sup>+&lt;/sup> CSC fractions from hepatocellular carcinoma cell lines. In Hep-12 cells, the Ca&lt;sup>2+&lt;/sup> oscillation frequency positively correlated with the self-renewal potential. Using a newly developed high signal, endoplasmic reticulum (ER) localized Ca&lt;sup>2+&lt;/sup> sensor GCaMP-ER2, we demonstrated CSC-distinctive oscillatory ER Ca&lt;sup>2+&lt;/sup> release controlled by the type 2 inositol 1,4,5-trisphosphate receptor (IP&lt;sub>3&lt;/sub>R2). Knockdown of IP&lt;sub>3&lt;/sub>R2 severely suppressed the self-renewal capacity of liver CSCs. We propose that targeting the IP&lt;sub>3&lt;/sub>R2-mediated Ca&lt;sup>2+&lt;/sup> oscillation in CSCs might afford a novel, physiologically inspired anti-tumor strategy for liver cancer.</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 May</publication><modification>2024-11-12T03:04:08.789Z</modification><creation>2019-06-06T23:18:17Z</creation></dates><accession>S-EPMC6529459</accession><cross_references><pubmed>31113961</pubmed><doi>10.1038/s41419-019-1613-2</doi></cross_references></HashMap>